3.20
Accendra Health Inc stock is traded at $3.20, with a volume of 2.48M.
It is down -17.74% in the last 24 hours and up +13.88% over the past month.
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
See More
Previous Close:
$3.89
Open:
$3.83
24h Volume:
2.48M
Relative Volume:
2.85
Market Cap:
$244.60M
Revenue:
$4.72B
Net Income/Loss:
$-123.85M
P/E Ratio:
-0.2238
EPS:
-14.2981
Net Cash Flow:
$-303.12M
1W Performance:
-14.89%
1M Performance:
+13.88%
6M Performance:
-82.02%
1Y Performance:
-82.02%
Accendra Health Inc Stock (ACH) Company Profile
Name
Accendra Health Inc
Sector
Industry
Phone
(804) 277-4304
Address
4435 WATERFRONT DRIVE, GLEN ALLEN
Compare ACH vs MCK, COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ACH
Accendra Health Inc
|
3.20 | 297.34M | 4.72B | -123.85M | -303.12M | -14.30 |
|
MCK
Mckesson Corp
|
734.69 | 87.17B | 403.43B | 5.10B | 5.41B | 38.47 |
|
COR
Cencora Inc
|
260.93 | 50.53B | 328.68B | 2.55B | 1.56B | 13.03 |
|
CAH
Cardinal Health Inc
|
182.56 | 42.74B | 250.74B | 1.55B | 4.39B | 6.5398 |
|
HSIC
Henry Schein Inc
|
69.35 | 7.86B | 13.18B | 419.00M | 521.00M | 3.2704 |
|
AHG
Akso Health Group Adr
|
2.115 | 1.81B | 14.85M | -136.07M | 7.25M | -0.4726 |
Accendra Health Inc Stock (ACH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Downgrade | UBS | Buy → Neutral |
| Jul-19-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Oct-13-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-26-22 | Resumed | Citigroup | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Mar-30-22 | Resumed | JP Morgan | Underweight |
| Mar-23-22 | Upgrade | HSBC Securities | Reduce → Hold |
| Apr-08-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-17-20 | Upgrade | UBS | Neutral → Buy |
| Sep-25-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-21-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-14-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-05-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Jan-21-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-07-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-15-19 | Upgrade | CLSA | Underperform → Outperform |
| Sep-06-19 | Reiterated | BofA/Merrill | Neutral |
| Apr-10-19 | Reiterated | BofA/Merrill | Neutral |
| Apr-03-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-01-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Jan-18-19 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-15-19 | Upgrade | CLSA | Underperform → Outperform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-12-18 | Downgrade | Goldman | Buy → Neutral |
| Sep-28-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-11-18 | Downgrade | CLSA | Outperform → Sell |
| Apr-10-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-26-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-17 | Downgrade | HSBC Securities | Buy → Hold |
| Mar-24-16 | Upgrade | Goldman | Sell → Neutral |
| Dec-07-15 | Downgrade | Goldman | Neutral → Sell |
| Aug-31-15 | Upgrade | Credit Suisse | Underperform → Neutral |
| Aug-01-12 | Initiated | HSBC Securities | Underweight |
| Aug-05-09 | Upgrade | Citigroup | Sell → Buy |
| Dec-01-08 | Downgrade | HSBC Securities | Neutral → Underweight |
View All
Accendra Health Inc Stock (ACH) Latest News
Accendra Health 1Q Adj Loss/Shr 4c >ACH - Moomoo
Accendra Health Inc (ACH) Q1 2026 Earnings Call Highlights: Navi - GuruFocus
Accendra Health To Effectuate Balance Sheet Optimization Transaction in Near Term >ACH - Moomoo
Accendra Health Shares Gain on Narrowed Loss, Adjusted EPS Beat - Moomoo
Accendra Health Q1 2026 slides: margins surge post-split, debt cut By Investing.com - Investing.com South Africa
Accendra Health cuts debt by $100M, extends maturities, but slow growth keeps EBITDA outlook cautious. - Pluang
Healthcare Firm Accendra Inks Discount Debt Exchange, New Funds - Bloomberg.com
Accendra Health Makes Progress Addressing Its Debt Load (NYSE:ACH) - Seeking Alpha
Accendra Health earnings beat by $0.06, revenue fell short of estimates - Investing.com Nigeria
Accendra Health Reports Q1 2026 Financial Results and Announces $1.5 Billion Balance Sheet Optimization Transaction - Minichart
Accendra Health 2026: Leading Home-Based Care Provider with Strong Financials, Growth Strategy, and Capital Structure Optimization - Minichart
Accendra Health 1Q 2026: Revenue $627.78M, EPS ($0.08) — 10-Q Summary - TradingView
Accendra Health (ACH) Q1 2026 loss, payor exit and major debt refi plan - Stock Titan
Earnings call transcript: Accendra Health beats EPS expectations in Q1 2026 - Investing.com UK
Accendra Health Q1 2026 slides: margins surge post-split, debt cut - Investing.com
Accendra Health (ACH) Shares Jump After First-Quarter Earnings Beat - Yahoo Finance
Accendra Health 1Q Loss/Shr 8c >ACH - Moomoo
Earnings call transcript: Accendra Health beats EPS expectations in Q1 2026 By Investing.com - Investing.com South Africa
Accendra Health reports Q1, announces $1.5B optimization - HME News
Accendra Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Accendra Health (ACH) Q1 Earnings Show Mixed Results - GuruFocus
Accendra Health reports Q1 EPS (4c) vs. 29c last year - TipRanks
Accendra Health (NYSE:ACH) Beats Q1 Estimates and Unveils $1.5B Debt Restructuring - ChartMill
Accendra Health Reports Q1 Loss, Launches Balance Sheet Plan - TipRanks
Accendra Health stock soars nearly 10% on first quarter earnings beat - Investing.com Australia
Accendra Health stock soars nearly 10% on first quarter earnings beat By Investing.com - Investing.com South Africa
Accendra Health (ACH) reworks debt with $326M 9% notes, $300M revolver and exchanges - Stock Titan
Accendra Health (NYSE: ACH) unveils $1.5B balance sheet overhaul with Q1 results - Stock Titan
Press Release: Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction - Moomoo
Owens & Minor Q1 2026 earnings preview - MSN
MSN Money - MSN
ACH Stock Price, Quote & Chart | ACCENDRA HEALTH INC (NYSE:ACH) - ChartMill
Why Accendra (ACH) business model holds up in any market (Investor Interest) 2026-05-08Community Trade Ideas - newser.com
Accendra Health Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference Call - Weekly Voice
Press Release: Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference Call - Moomoo
ACH News | ACCENDRA HEALTH INC (NYSE:ACH) - ChartMill
Accendra Health (formerly Owens & Minor) discloses executive pay - Medical Design & Outsourcing
Accendra Health (ACH) price target decreased by 69.55% to 3.77 - MSN
Owens & Minor to rebrand as Accendra Health, change ticker to "ACH" - MSN
Is the Options Market Predicting a Spike in Accendra Health Stock? - MSN
ACH Financials: Income Statement, Balance Sheet & Cash Flow | Accendra Health Inc - Stock Titan
ACH Stock Price, News & Analysis | Accendra Health - Stock Titan
Lobbying Update: $280,000 of ACCENDRA HEALTH INC. (FORMERLY "OWENS & MINOR INC.") lobbying was just disclosed - Quiver Quantitative
ACH Options Volatility — NYSE:ACH - TradingView
Is Accendra (ACH) Stock Underperforming | Price at $2.65, Up 0.95%Popular Trader Picks - Cổng thông tin điện tử tỉnh Lào Cai
OMI.N Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Accendra Health Inc Stock (ACH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):